Okogen is a developer of ophthalmic anti-infective drugs.
Okogen has raised $3.3M in total funding. The most recent round was Undisclosed. The last funding was announced in December 2024.
Okogen's investors include Brandon Capital, Medical Research Commercialisation Fund (MRCF).
Okogen is headquartered in Encinitas, United States.
Okogen is a developer of ophthalmic anti-infective drugs.
Okogen is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Okogen — Funding & Investors." VCBacked, December 11, 2024, https://www.vcbacked.co/company/okogen. Accessed September 30, 2026.
VCBacked. (2024). Okogen — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/okogen
{{cite web |title=Okogen — Funding & Investors |url=https://www.vcbacked.co/company/okogen |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated